1. Scrip
  2. >>Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

cardiovascular system
Marea hopes ANGPTL4 inhibition can benefit high-risk cardiovascular patients • Source: Shutterstock

Unveiled in 2024 with $190m in combined series A and B financing, Marea Therapeutics is aiming high by seeking to eventually demonstrate a cardioprotective benefit for MAR001, its Phase II ANGPTL4-targeted antibody. The South San Francisco firm reported positive Phase IIa data for three doses of MAR001 at the European Atherosclerosis Society Congress in Scotland on 7 May and plans to initiate a Phase IIb trial later this year.

Key Takeaways
  • 2024 start-up Marea presented Phase IIa data showing that its ANGPTL4-targeted antibody can reduce triglycerides and remnant cholesterol.

In an interview, Marea CEO Josh Lehrer said that although there might be quicker and less resource-expensive ways to bring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from R&D

Pipeline Watch: Five Approvals And Twelve Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.